Substance / Medication

Thioguanine

Overview

Active Ingredient
thioguanine
RxNorm CUI
10485
Labeler: Waylis Therapeutics LLCUpdated: 2025-01-08T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Thioguanine should not be used in patients whose disease has demonstrated prior resistance to this drug. In animals and humans, there is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

145 trials linked to this intervention

145
Total Trials
25
Recruiting
61
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effectiveness and safety of thioguanine as a maintenance therapy of inflammatory bowel disease: Systematic review, meta-analysis and meta-regression.
Jena Anuraag, Neelam Pardhu B, Telaprolu Harshavardhan et al. · Clin Res Hepatol Gastroenterol · 2023
PMID: 37301255Meta-Analysis
DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.
Toksvang Linea N, Grell Kathrine, Nersting Jacob et al. · Leukemia · 2022
PMID: 34175901Meta-Analysis
Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review.
Toksvang Linea Natalie, Schmidt Magnus Strøh, Arup Sofie et al. · PLoS One · 2019
PMID: 31125338Meta-AnalysisFull text (PMC)
A Systematic Review and Meta-Analysis of 6-Thioguanine Nucleotide Levels and Clinical Remission in Inflammatory Bowel Disease.
Estevinho Maria Manuela, Afonso Joana, Rosa Isadora et al. · J Crohns Colitis · 2017
PMID: 28981590Meta-Analysis
Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review.
Meijer Berrie, Mulder Chris Jj, Peters Godefridus J et al. · World J Gastroenterol · 2016
PMID: 27833392Meta-AnalysisFull text (PMC)
Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis.
Moreau Amelie Carla, Paul Stephane, Del Tedesco Emilie et al. · Inflamm Bowel Dis · 2014
PMID: 24418904Meta-Analysis
Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis.
Osterman Mark T, Kundu Rabi, Lichtenstein Gary R et al. · Gastroenterology · 2006
PMID: 16618398Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tioguanine (substance)
SNOMED CT
387407006
UMLS CUI
C0039902
RxNorm CUI
10485
Labeler
Waylis Therapeutics LLC

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
145
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.